CTOs on the Move

Barenburg Eye

www.barenburgeye.com

 
Barenburg Eye is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Autonomic Technologies

Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.

Detroit Institute for Children

Detroit Institute for Children is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visa Solutions Healthcare

Visa Solutions Healthcare is a healthcare division that connects partners with highly qualified international registered nurses and allied clinicians. They offer a Care for your Dream program to help nurses work in the U.S. and provide diagnostics so...

OtisMed Corporation

OtisMed Corporation is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.